Company profile
Kesmalea Therapeutics
Transforming protein degradation to create new medicines: A new class of oral, CNS penetrant protein degraders.
- Industry
- Biotechnology Research
- Employees
- 21
- Headquarters
- London
- Office locations
- 1
Kesmalea Therapeutics company summary
Kesmalea Therapeutics is a company in the Biotechnology Research industry, headquartered in London. On LinkedIn the company has around 21 employees.
What technology does Kesmalea Therapeutics use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Kesmalea Therapeutics
Kesmalea is developing a pipeline of novel therapeutics founded on the ability to transform large protein degraders into small molecules. This is achieved through SELFTAC®, a platform designed to combine the power of protein degradation with advantages such as oral bioavailability and central nervous system (CNS) penetration, among other attributes. Kesmalea’s current research spans targets in oncology and diseases of the CNS, with broader applicability. The company is built on foundational scientific work by founder & CSO Harry Finch, Ph.D., a noted medicinal chemist and entrepreneur.
Where is Kesmalea Therapeutics located?
Kesmalea Therapeutics lists 1 location.
Compare companies similar to Kesmalea Therapeutics
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Kesmalea Therapeutics kesmalea.com | Biotechnology Research | 21 | - | London |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about Kesmalea Therapeutics
What does Kesmalea Therapeutics do?
Kesmalea is developing a pipeline of novel therapeutics founded on the ability to transform large protein degraders into small molecules. This is achieved through SELFTAC®, a platform designed to combine the power of protein degradation with advantages such as oral bioavailability and central nervous system (CNS) penetration, among other attributes. Kesmalea’s current research spans targets in oncology and diseases of the CNS, with broader applicability. The company is built on foundational scientific work by founder & CSO Harry Finch, Ph.D., a noted medicinal chemist and entrepreneur.
How many employees does Kesmalea Therapeutics have?
Kesmalea Therapeutics has around 21 employees on LinkedIn.
Where is Kesmalea Therapeutics headquartered?
Kesmalea Therapeutics is headquartered in London.
Build a lead list from companies like Kesmalea Therapeutics
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.